Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators. Gelmon KA, et al. Among authors: walker g. Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1. Eur J Cancer. 2021. PMID: 34087573 Free article. Clinical Trial.
Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O'Shaughnessy J, Balmaña J. Koh SJ, et al. Among authors: walker g. Breast Cancer. 2022 Jan;29(1):92-102. doi: 10.1007/s12282-021-01283-4. Epub 2021 Aug 31. Breast Cancer. 2022. PMID: 34467476 Free PMC article.
Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O'Shaughnessy J, Balmaña J. Koh SJ, et al. Among authors: walker g. Breast Cancer. 2022 Jan;29(1):189-190. doi: 10.1007/s12282-021-01299-w. Breast Cancer. 2022. PMID: 34562259 Free PMC article. No abstract available.
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies.
Mazigi O, Langley DB, Henry JY, Burnett DL, Sobti M, Walker GJ, Rouet R, Balachandran H, Lenthall H, Jackson J, Ubiparipovic S, Schofield P, Brown SHJ, Schulz SR, Hoffmann M, Pöhlmann S, Post J, Martinello M, Ahlenstiel G, Kelleher A, Rawlinson WD, Turville SG, Bull RA, Stewart AG, Jäck HM, Goodnow CC, Christ D. Mazigi O, et al. Among authors: walker gj. Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2417544121. doi: 10.1073/pnas.2417544121. Epub 2025 Jan 2. Proc Natl Acad Sci U S A. 2025. PMID: 39746041 Free PMC article.
2,618 results